What Is Cyclosporin H: Mechanism and Research Uses

Cyclosporin H is a naturally occurring cyclic peptide that blocks a specific receptor on immune cells called formyl peptide receptor 1 (FPR1), making it a valuable laboratory tool for studying inflammation, infection, and immune cell behavior. Despite sharing a name and a fungal origin with the famous immunosuppressant cyclosporin A, cyclosporin H does not suppress the immune system in the same way. Its primary value lies in its ability to selectively shut down one signaling pathway that white blood cells use to detect and respond to bacterial invaders and tissue damage, and that distinction has made it a fixture in immunology and cell biology research.

How Cyclosporin H Differs from Cyclosporin A

Cyclosporin A is one of the most widely used immunosuppressive drugs in medicine, prescribed to prevent organ transplant rejection and treat autoimmune diseases. It works by binding to an intracellular protein called cyclophilin, which in turn blocks the enzyme calcineurin and suppresses T-cell activation. Cyclosporin H does none of that. It is a closely related molecule, also an eleven-amino-acid ring (an undecapeptide) produced by the fungus Tolypocladium inflatum, but a single structural difference changes its biological activity entirely.

The critical distinction is a modified amino acid at position 11 of the ring. Cyclosporin H has N-methyl-D-valine at that position, while other cyclosporins (A, B, C, D, E) do not. Research comparing these variants confirmed that this residue is crucial for the ability to antagonize the formyl peptide receptor; removing or replacing it eliminates the FPR1-blocking activity.¹ The total chemical synthesis of cyclosporin H was achieved in the 1980s, confirming its structure as [D-MeVal¹¹]cyclosporine.²

So while cyclosporin A dampens the adaptive immune system by silencing T cells, cyclosporin H targets a completely different arm of immunity: the innate system, specifically the receptor through which neutrophils and other cells detect formylated peptides. This makes the two compounds useful for entirely different purposes in the lab.

What FPR1 Does and Why Blocking It Matters

FPR1 sits on the surface of neutrophils, monocytes, basophils, and certain other immune cells. Its natural job is to detect formylated peptides, short protein fragments that begin with a formyl-methionine residue. Bacteria produce these peptides as part of normal protein synthesis, and when they leak from an infection site, FPR1 acts as an alarm sensor. Once a formylated peptide docks onto FPR1, the receptor triggers a cascade of responses: the cell rushes toward the signal (chemotaxis), releases tissue-damaging reactive oxygen species like superoxide, and dumps inflammatory enzymes from internal granules.

This system is essential for fighting infection, but it can also cause collateral damage. In trauma, surgery, or critical illness, the body’s own mitochondria release formylated peptides (since mitochondria evolved from bacteria and still produce formyl-methionine-tagged proteins). These endogenous signals can activate FPR1 just like bacterial peptides do, driving inflammation that damages healthy tissue rather than fighting an actual infection.

Cyclosporin H gives researchers a way to switch FPR1 off in a controlled manner, which lets them ask targeted questions: how much of the inflammatory response in a given disease or injury is driven specifically by FPR1 signaling, and what happens when you remove that contribution?

Potency and How the Blocking Works

Cyclosporin H is a competitive antagonist, meaning it physically occupies the same binding pocket on FPR1 that the natural formylated peptide agonist (commonly abbreviated fMLF or FMLP in lab contexts) would use. Because it sits in the binding site without activating the receptor, it prevents the real signal from getting through. The more cyclosporin H present, the higher the concentration of agonist needed to overcome the blockade, which is exactly the pattern researchers observed in neutrophil experiments.

In human neutrophils, cyclosporin H inhibited superoxide production triggered by fMLF with a half-maximal effect at a concentration of just 40 nanomolar, and it completely abolished the response at 1 micromolar. It also shifted the dose-response curve for fMLF dramatically, increasing the concentration of fMLF needed for half-maximal activation by roughly 25-fold.³ Detailed binding studies confirmed the mechanism, showing that cyclosporin H binds to FPR1 with an inhibition constant of about 0.1 micromolar for the ligand-binding site itself, and blocks downstream signaling events including calcium mobilization, enzyme release, and GTPase activation at similarly low concentrations.¹

For researchers accustomed to older FPR antagonists like BocMLP and related synthetic peptides, cyclosporin H represented a major step up. Head-to-head comparisons showed it was far more potent: the concentration needed to inhibit radiolabeled fMLF binding to white blood cells was roughly 170-fold lower for cyclosporin H than for BocMLP.⁴

Selectivity for FPR1 Over Its Relatives

Humans have a small family of formyl peptide receptors: FPR1, FPR2 (also called FPRL1), and FPR3. These receptors overlap in some of their ligand preferences, which creates a problem for researchers trying to dissect which receptor drives a particular response. A tool that blocks all three at once cannot tell you which one matters.

Cyclosporin H is useful precisely because it preferentially targets FPR1. At concentrations sufficient to fully block FPR1-mediated signaling, it leaves FPR2 largely untouched. In a systematic comparison with other antagonists, signaling through FPR1 was blocked by low concentrations of cyclosporin H, while substantially higher concentrations were needed to partially inhibit FPR2. The study’s authors recommended cyclosporin H as the antagonist of choice when researchers need to distinguish FPR1-driven responses from FPR2-driven ones.⁵

That selectivity has been validated in multiple cell types. In basophils, for instance, cyclosporin H blocked histamine and leukotriene C4 release triggered by fMLF in a dose-dependent manner, whereas cyclosporin A at the same concentrations had little effect on fMLF-induced basophil activation.⁴ This reinforces the idea that cyclosporin H’s activity is about FPR1 blockade, not a broader immunosuppressive effect.

Unraveling Mitochondrial Danger Signals in Trauma

One of the most impactful research applications for cyclosporin H has been in understanding how the body’s own mitochondria drive harmful inflammation after injury. When cells are damaged by trauma, surgery, or ischemia, mitochondria break open and release their contents into the bloodstream. Among those contents are formylated peptides that look, to the immune system, like bacterial invaders. Neutrophils detect these mitochondrial signals through FPR1 and mount a full inflammatory response, which in serious cases can escalate into conditions like acute respiratory distress syndrome or systemic inflammatory response syndrome.

Cyclosporin H has been central to proving that formylated peptides, rather than other mitochondrial components, are the primary drivers of this response. In experiments with neutrophils exposed to mitochondrial damage-associated molecular patterns, pre-treatment with cyclosporin H significantly blocked the shedding of L-selectin (a marker of neutrophil activation) as well as the activation of key signaling enzymes, suggesting that FPR1-detected formyl peptides are the main constituents driving the inflammatory cascade.⁶ Similarly, in a study using material collected during orthopedic surgery (femoral reamings), neutrophil activation by mitochondrial debris was inhibited by cyclosporin H, confirming the involvement of FPR1 in a clinically relevant surgical setting.⁷

In lung injury research, cyclosporin H proved that FPR1 mediates the neutrophil response to mitochondrial formylated peptides released during acute respiratory distress. Pre-treatment with cyclosporin H blocked the upregulation of adhesion molecules on neutrophils and abolished chemotaxis toward mitochondrial peptides, effects that tracked closely with what was seen using anti-FPR1 antibodies.⁸ These findings collectively built a strong case that FPR1 is a potential therapeutic target in post-traumatic inflammation, a line of reasoning that would have been much harder to establish without a selective antagonist like cyclosporin H.

Uses in Cancer Biology

FPR1 is not limited to neutrophils and other classic immune cells. Certain tumors also express the receptor, and researchers have used cyclosporin H to explore what FPR1 signaling does in those contexts. In neuroblastoma cells, stimulating FPR1 with its natural agonist activated multiple cancer-relevant signaling cascades, including the MAPK/Erk, PI3K/Akt, and p38-MAPK pathways. All of these responses were blocked when the cells were pre-treated with cyclosporin H, confirming that the effects ran specifically through FPR1.⁹

FPR1 involvement has been studied in other tumor types as well, with cyclosporin H serving as the standard pharmacological tool to determine whether observed effects on cell migration, proliferation, or survival depend on this receptor. While cyclosporin H is far from being a cancer drug itself, it has helped map out the biology of FPR1 in tumors, which could inform future drug development aimed at that receptor.

Improving Gene Therapy with Cyclosporin H

A more unexpected application emerged in gene therapy research. Lentiviral vectors, a common tool for delivering therapeutic genes into human blood stem cells, face a problem: the cells’ own innate immune defenses recognize viral components and resist transduction. Researchers found that cyclosporin H could overcome these innate immune barriers, improving the efficiency of lentiviral gene transfer and gene editing in human hematopoietic stem cells. The work revealed that innate pathogen-recognition molecules create blocks to gene correction in primary stem cells and showed that FPR1 antagonism with cyclosporin H was one way to lower those barriers.¹⁰

This is a practical application with direct implications for patients with genetic blood disorders. If stem cells resist the gene therapy vector because their immune sensors detect it as a threat, dampening that specific sensor could make the difference between a therapy that works reliably and one with inconsistent results. The fact that cyclosporin H acts on a narrow receptor rather than broadly suppressing immune function is an advantage here, since broad immunosuppression in stem cells headed for transplant would create its own risks.

Emerging Work in Sepsis and Kidney Injury

More recent research has begun testing whether cyclosporin H might have therapeutic potential beyond its role as a lab tool. In a sepsis-induced acute kidney injury model, cyclosporin H treatment significantly reduced kidney tissue damage, lowered markers of impaired kidney function, and decreased levels of inflammatory proteins. The treatment also reduced signs of pyroptosis, a form of inflammatory cell death, with lower levels of key proteins in the pyroptosis pathway (NLRP3, caspase-1, ASC, and IL-1β) and less mitochondrial damage visible under electron microscopy.¹¹

These findings are preclinical and early-stage, but they suggest that the FPR1 pathway contributes to organ damage in sepsis and that blocking it pharmacologically can be protective. Whether cyclosporin H itself could become a therapeutic agent, or whether it simply points the way toward a druggable target, remains to be seen.

Genetic Variation in FPR1 Changes the Story

Not everyone’s FPR1 receptor is identical. A naturally occurring genetic variant swaps valine for leucine at position 101 of the receptor protein. This single amino acid change turns out to significantly affect how well cyclosporin H (and cyclosporin A) bind to and block FPR1. Cells carrying the leucine variant showed higher binding affinity for cyclosporins, and the antagonism was correspondingly stronger: calcium mobilization, chemotaxis, and MAPK signaling were all more effectively inhibited by cyclosporins in cells with this variant.¹²

For researchers, this means that results from cyclosporin H experiments could vary depending on which FPR1 variant the donor cells carry. It also raises the possibility that if FPR1 antagonism ever reaches the clinic, patients might respond differently based on their genotype. This kind of pharmacogenomic wrinkle is common in drug development, but in the case of cyclosporin H, the receptor-level mechanism has been mapped in unusual detail.

The Mouse Problem

A significant limitation of cyclosporin H that every researcher working with animal models needs to know: it does not work on the mouse version of FPR1. The mouse orthologue, called Fpr1 (lowercase, per naming conventions), differs enough in its binding pocket that cyclosporin H is simply not recognized. In experiments with mouse neutrophils, neither cyclosporin H nor the related antagonist BOC1 could inhibit fMIFL-induced NADPH oxidase activity, even at concentrations well above what would fully block the human receptor. A different antagonist, BOC2, did work on the mouse receptor.¹³

This species-specific limitation is not unique to cyclosporin H; many FPR1 ligands show poor cross-reactivity between human and mouse receptors. But it has practical consequences. Researchers who want to study FPR1 blockade in a mouse model of disease or injury cannot simply inject cyclosporin H and expect informative results. They need to use alternative antagonists, genetic knockouts, or humanized mouse models. Studies that use cyclosporin H on human cells in vitro and then switch to BOC2 or genetic approaches for in vivo mouse work are a common design pattern in this field, and understanding why requires knowing about this species mismatch.

Where Cyclosporin H Fits Among FPR1 Antagonists

Cyclosporin H is not the only FPR1 antagonist available, but it has held a privileged position for three decades because of its combination of potency and selectivity for human FPR1. Older peptide antagonists like BocMLP and related Boc-peptides are less potent and less selective. Newer small-molecule antagonists are now entering the picture. One compound, AZ2158, has been reported to be more potent than cyclosporin H in blocking neutrophil chemotaxis toward formylated peptides, though it shares the same species limitation of not working on mouse Fpr1.¹³

The emergence of alternatives does not diminish cyclosporin H’s role. Decades of published data use it as the reference standard for FPR1 blockade, meaning any new antagonist is benchmarked against it. And because it is a natural product with well-characterized pharmacology, it remains a reliable first-line choice for in vitro experiments with human cells. Its limitations are well mapped: it does not cross species boundaries easily, it does not block FPR2 or FPR3 at standard working concentrations, and it has no significant immunosuppressive activity through the cyclosporin A pathway. For a research tool, having clearly defined limits is almost as valuable as having strong effects.